These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 28531814)

  • 1. Targeting EGFR/HER2 heterodimerization with a novel anti-HER2 domain II/III antibody.
    Yu X; Wang L; Shen Y; Wang C; Zhang Y; Meng Y; Yang Y; Liang B; Zhou B; Wang H; Wei H; Lei C; Hu S; Li B
    Mol Immunol; 2017 Jul; 87():300-307. PubMed ID: 28531814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insights into HER2 signaling from step-by-step optimization of anti-HER2 antibodies.
    Fu W; Wang Y; Zhang Y; Xiong L; Takeda H; Ding L; Xu Q; He L; Tan W; Bethune AN; Zhou L
    MAbs; 2014; 6(4):978-90. PubMed ID: 24838231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural and functional characterization of MBS301, an afucosylated bispecific anti-HER2 antibody.
    Huang S; Li F; Liu H; Ye P; Fan X; Yuan X; Wu Z; Chen J; Jin C; Shen B; Feng J; Zhang B
    MAbs; 2018; 10(6):864-875. PubMed ID: 30081724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HER2 monoclonal antibodies that do not interfere with receptor heterodimerization-mediated signaling induce effective internalization and represent valuable components for rational antibody-drug conjugate design.
    de Goeij BE; Peipp M; de Haij S; van den Brink EN; Kellner C; Riedl T; de Jong R; Vink T; Strumane K; Bleeker WK; Parren PW
    MAbs; 2014; 6(2):392-402. PubMed ID: 24492309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-epidermal growth factor receptor monoclonal antibody cetuximab inhibits EGFR/HER-2 heterodimerization and activation.
    Patel D; Bassi R; Hooper A; Prewett M; Hicklin DJ; Kang X
    Int J Oncol; 2009 Jan; 34(1):25-32. PubMed ID: 19082474
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and Characterization of a Humanized Anti-HER2 Antibody HuA21 with Potent Anti-Tumor Properties in Breast Cancer Cells.
    Li R; Hu S; Chang Y; Zhang Z; Zha Z; Huang H; Shen G; Liu J; Song L; Wei W
    Int J Mol Sci; 2016 Apr; 17(4):563. PubMed ID: 27092488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models.
    Scheuer W; Friess T; Burtscher H; Bossenmaier B; Endl J; Hasmann M
    Cancer Res; 2009 Dec; 69(24):9330-6. PubMed ID: 19934333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bispecific antibody to ErbB2 overcomes trastuzumab resistance through comprehensive blockade of ErbB2 heterodimerization.
    Li B; Meng Y; Zheng L; Zhang X; Tong Q; Tan W; Hu S; Li H; Chen Y; Song J; Zhang G; Zhao L; Zhang D; Hou S; Qian W; Guo Y
    Cancer Res; 2013 Nov; 73(21):6471-83. PubMed ID: 24046294
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic antitumor efficacy against the EGFRvIII+HER2+ breast cancers by combining trastuzumab with anti-EGFRvIII antibody CH12.
    Xu W; Bi Y; Zhang J; Kong J; Jiang H; Tian M; Li K; Wang B; Chen C; Song F; Pan X; Shi B; Kong X; Gu J; Cai X; Li Z
    Oncotarget; 2015 Nov; 6(36):38840-53. PubMed ID: 26474285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy.
    Lee-Hoeflich ST; Crocker L; Yao E; Pham T; Munroe X; Hoeflich KP; Sliwkowski MX; Stern HM
    Cancer Res; 2008 Jul; 68(14):5878-87. PubMed ID: 18632642
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biology of HER2 and its importance in breast cancer.
    Yarden Y
    Oncology; 2001; 61 Suppl 2():1-13. PubMed ID: 11694782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effective suppression of breast tumor growth by an anti-EGFR/ErbB2 bispecific antibody.
    Wang S; Chen C; Meng Y; Hu S; Zheng L; Song J; Zhang D; Li B; Guo Y
    Cancer Lett; 2012 Dec; 325(2):214-9. PubMed ID: 22789781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting HER2+ breast cancer cells: lysosomal accumulation of anti-HER2 antibodies is influenced by antibody binding site and conjugation to polymeric nanoparticles.
    Owen SC; Patel N; Logie J; Pan G; Persson H; Moffat J; Sidhu SS; Shoichet MS
    J Control Release; 2013 Dec; 172(2):395-404. PubMed ID: 23880472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update on HER-kinase-directed therapy in prostate cancer.
    Gross ME; Jo S; Agus DB
    Clin Adv Hematol Oncol; 2004 Jan; 2(1):53-6, 64. PubMed ID: 16163160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modular anti-EGFR and anti-Her2 targeting of SK-BR-3 and BT474 breast cancer cell lines in the presence of ErbB receptor-specific growth factors.
    Diermeier-Daucher S; Breindl S; Buchholz S; Ortmann O; Brockhoff G
    Cytometry A; 2011 Sep; 79(9):684-93. PubMed ID: 21786419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
    Moulder SL; Yakes FM; Muthuswamy SK; Bianco R; Simpson JF; Arteaga CL
    Cancer Res; 2001 Dec; 61(24):8887-95. PubMed ID: 11751413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MicroSPECT/CT imaging of co-expressed HER2 and EGFR on subcutaneous human tumor xenografts in athymic mice using ¹¹¹In-labeled bispecific radioimmunoconjugates.
    Razumienko E; Dryden L; Scollard D; Reilly RM
    Breast Cancer Res Treat; 2013 Apr; 138(3):709-18. PubMed ID: 23525982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The ErbB/HER family of protein-tyrosine kinases and cancer.
    Roskoski R
    Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A systematic review of dual targeting in HER2-positive breast cancer.
    Kümler I; Tuxen MK; Nielsen DL
    Cancer Treat Rev; 2014 Mar; 40(2):259-70. PubMed ID: 24080156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential action of small molecule HER kinase inhibitors on receptor heterodimerization: therapeutic implications.
    Sánchez-Martín M; Pandiella A
    Int J Cancer; 2012 Jul; 131(1):244-52. PubMed ID: 21826647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.